Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria
Chronic urticaria (CU) imposes profound impairment on patient's quality of life. Our study was done to evaluate the clinical efficacy and safety of desloratadine combined with dipyridamole, which is a platelet adhesion inhibitor in the treatment of CU. A randomized study was done in 64 autoimmu...
Gespeichert in:
| Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2008-04, Vol.22 (4), p.487-492 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 492 |
|---|---|
| container_issue | 4 |
| container_start_page | 487 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 22 |
| creator | Khalaf, AT Liu, X-M Sheng, W-X Tan, JQ Abdalla, AN |
| description | Chronic urticaria (CU) imposes profound impairment on patient's quality of life. Our study was done to evaluate the clinical efficacy and safety of desloratadine combined with dipyridamole, which is a platelet adhesion inhibitor in the treatment of CU. A randomized study was done in 64 autoimmunity CU patients with positive autologous plasma skin test (APST): 34 patients as treatment and 30 controls. The treatment group was treated with desloratadine and dipyridamole, and the control group was treated with desloratadine only. The efficiency and side‐effect were evaluated at the end of treatment. The levels of fragment F1+2 were measured by enzyme‐linked immunosorbent assay in all patients at pre‐ and post‐treatment. The clinical effectiveness rates of treatment and control group were, respectively, 85.20% (21 cured, 8 obvious effectiveness) and 70% (14 cured, 7 obvious effectiveness); they have a significant difference (x = 4.09, P |
| doi_str_mv | 10.1111/j.1468-3083.2007.02511.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70430161</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70430161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4051-2b084688c7a7532b4d572b1e29201da41672feb47b221b4952676a2fa2ab13e03</originalsourceid><addsrcrecordid>eNqNkMlu2zAURYkiReOk_YWCq-yk8lEDpUUXQaYmsNNNpx3B4Qmmq8EhacT6-0qxkWzLzSPAe-4jDiEUWArT-bJJIS-rJGNVlnLGRMp4AZDu35HF68MJWbCal0ldF_UpOQthwxgDKKoP5BQqVoHIxYLgTdM4o8xIVW9pUA3GkQ4NtRjawauorOuRmqHT07T02cU1tW47emdVN7RIXU_jGmn0qGKHfZxhs_ZD7wzd-Th1e6c-kveNagN-Os5z8vP25sfVt2T5_e7-6nKZmJwVkHDNqun7lRFKFBnXuS0E14C85gysyqEUvEGdC8056LwueClKxRvFlYYMWXZOLg69Wz887TBE2blgsG1Vj8MuSMHyjEEJU7A6BI0fQvDYyK13nfKjBCZnxXIjZ5NyNilnxfJFsdxP6Ofjjp3u0L6BR6dT4Osh8OxaHP-7WD5c_5pvE58ceBci7l955f_KUmSikL8f7-TDn3q5Wj2u5HX2D72emb4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70430161</pqid></control><display><type>article</type><title>Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Khalaf, AT ; Liu, X-M ; Sheng, W-X ; Tan, JQ ; Abdalla, AN</creator><creatorcontrib>Khalaf, AT ; Liu, X-M ; Sheng, W-X ; Tan, JQ ; Abdalla, AN</creatorcontrib><description>Chronic urticaria (CU) imposes profound impairment on patient's quality of life. Our study was done to evaluate the clinical efficacy and safety of desloratadine combined with dipyridamole, which is a platelet adhesion inhibitor in the treatment of CU. A randomized study was done in 64 autoimmunity CU patients with positive autologous plasma skin test (APST): 34 patients as treatment and 30 controls. The treatment group was treated with desloratadine and dipyridamole, and the control group was treated with desloratadine only. The efficiency and side‐effect were evaluated at the end of treatment. The levels of fragment F1+2 were measured by enzyme‐linked immunosorbent assay in all patients at pre‐ and post‐treatment. The clinical effectiveness rates of treatment and control group were, respectively, 85.20% (21 cured, 8 obvious effectiveness) and 70% (14 cured, 7 obvious effectiveness); they have a significant difference (x = 4.09, P < 0.05). Before treatment, the weals and pruritus in the treatment and control group were, respectively, (1.74 ± 0.90, 1.79 ± 0.73) and (1.67 ± 0.84, 1.73 ± 0.78). After treatment, the weals and pruritus in treatment and control group were, respectively, (0.38 ± 0.73, 0.58 ± 0.89) and (0.67 ± 0.96, 1.10 ± 1.12). These findings provide new insights into the pathogenesis of CU and suggest new therapeutic opportunities for treating this disease.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/j.1468-3083.2007.02511.x</identifier><identifier>PMID: 18081747</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Chronic Disease ; chronic urticaria (CU) ; desloratadine ; dipyridamole ; Dipyridamole - administration & dosage ; Dipyridamole - therapeutic use ; Drug Therapy, Combination ; F1+2 ; Female ; Histamine H1 Antagonists, Non-Sedating - administration & dosage ; Histamine H1 Antagonists, Non-Sedating - therapeutic use ; Humans ; Loratadine - administration & dosage ; Loratadine - analogs & derivatives ; Loratadine - therapeutic use ; Male ; Middle Aged ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - therapeutic use ; Skin Tests ; Treatment Outcome ; Urticaria - drug therapy</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2008-04, Vol.22 (4), p.487-492</ispartof><rights>2007 The Authors</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4051-2b084688c7a7532b4d572b1e29201da41672feb47b221b4952676a2fa2ab13e03</citedby><cites>FETCH-LOGICAL-c4051-2b084688c7a7532b4d572b1e29201da41672feb47b221b4952676a2fa2ab13e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1468-3083.2007.02511.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1468-3083.2007.02511.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18081747$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khalaf, AT</creatorcontrib><creatorcontrib>Liu, X-M</creatorcontrib><creatorcontrib>Sheng, W-X</creatorcontrib><creatorcontrib>Tan, JQ</creatorcontrib><creatorcontrib>Abdalla, AN</creatorcontrib><title>Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Chronic urticaria (CU) imposes profound impairment on patient's quality of life. Our study was done to evaluate the clinical efficacy and safety of desloratadine combined with dipyridamole, which is a platelet adhesion inhibitor in the treatment of CU. A randomized study was done in 64 autoimmunity CU patients with positive autologous plasma skin test (APST): 34 patients as treatment and 30 controls. The treatment group was treated with desloratadine and dipyridamole, and the control group was treated with desloratadine only. The efficiency and side‐effect were evaluated at the end of treatment. The levels of fragment F1+2 were measured by enzyme‐linked immunosorbent assay in all patients at pre‐ and post‐treatment. The clinical effectiveness rates of treatment and control group were, respectively, 85.20% (21 cured, 8 obvious effectiveness) and 70% (14 cured, 7 obvious effectiveness); they have a significant difference (x = 4.09, P < 0.05). Before treatment, the weals and pruritus in the treatment and control group were, respectively, (1.74 ± 0.90, 1.79 ± 0.73) and (1.67 ± 0.84, 1.73 ± 0.78). After treatment, the weals and pruritus in treatment and control group were, respectively, (0.38 ± 0.73, 0.58 ± 0.89) and (0.67 ± 0.96, 1.10 ± 1.12). These findings provide new insights into the pathogenesis of CU and suggest new therapeutic opportunities for treating this disease.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Chronic Disease</subject><subject>chronic urticaria (CU)</subject><subject>desloratadine</subject><subject>dipyridamole</subject><subject>Dipyridamole - administration & dosage</subject><subject>Dipyridamole - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>F1+2</subject><subject>Female</subject><subject>Histamine H1 Antagonists, Non-Sedating - administration & dosage</subject><subject>Histamine H1 Antagonists, Non-Sedating - therapeutic use</subject><subject>Humans</subject><subject>Loratadine - administration & dosage</subject><subject>Loratadine - analogs & derivatives</subject><subject>Loratadine - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Skin Tests</subject><subject>Treatment Outcome</subject><subject>Urticaria - drug therapy</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMlu2zAURYkiReOk_YWCq-yk8lEDpUUXQaYmsNNNpx3B4Qmmq8EhacT6-0qxkWzLzSPAe-4jDiEUWArT-bJJIS-rJGNVlnLGRMp4AZDu35HF68MJWbCal0ldF_UpOQthwxgDKKoP5BQqVoHIxYLgTdM4o8xIVW9pUA3GkQ4NtRjawauorOuRmqHT07T02cU1tW47emdVN7RIXU_jGmn0qGKHfZxhs_ZD7wzd-Th1e6c-kveNagN-Os5z8vP25sfVt2T5_e7-6nKZmJwVkHDNqun7lRFKFBnXuS0E14C85gysyqEUvEGdC8056LwueClKxRvFlYYMWXZOLg69Wz887TBE2blgsG1Vj8MuSMHyjEEJU7A6BI0fQvDYyK13nfKjBCZnxXIjZ5NyNilnxfJFsdxP6Ofjjp3u0L6BR6dT4Osh8OxaHP-7WD5c_5pvE58ceBci7l955f_KUmSikL8f7-TDn3q5Wj2u5HX2D72emb4</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>Khalaf, AT</creator><creator>Liu, X-M</creator><creator>Sheng, W-X</creator><creator>Tan, JQ</creator><creator>Abdalla, AN</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200804</creationdate><title>Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria</title><author>Khalaf, AT ; Liu, X-M ; Sheng, W-X ; Tan, JQ ; Abdalla, AN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4051-2b084688c7a7532b4d572b1e29201da41672feb47b221b4952676a2fa2ab13e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Chronic Disease</topic><topic>chronic urticaria (CU)</topic><topic>desloratadine</topic><topic>dipyridamole</topic><topic>Dipyridamole - administration & dosage</topic><topic>Dipyridamole - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>F1+2</topic><topic>Female</topic><topic>Histamine H1 Antagonists, Non-Sedating - administration & dosage</topic><topic>Histamine H1 Antagonists, Non-Sedating - therapeutic use</topic><topic>Humans</topic><topic>Loratadine - administration & dosage</topic><topic>Loratadine - analogs & derivatives</topic><topic>Loratadine - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Skin Tests</topic><topic>Treatment Outcome</topic><topic>Urticaria - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khalaf, AT</creatorcontrib><creatorcontrib>Liu, X-M</creatorcontrib><creatorcontrib>Sheng, W-X</creatorcontrib><creatorcontrib>Tan, JQ</creatorcontrib><creatorcontrib>Abdalla, AN</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khalaf, AT</au><au>Liu, X-M</au><au>Sheng, W-X</au><au>Tan, JQ</au><au>Abdalla, AN</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2008-04</date><risdate>2008</risdate><volume>22</volume><issue>4</issue><spage>487</spage><epage>492</epage><pages>487-492</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Chronic urticaria (CU) imposes profound impairment on patient's quality of life. Our study was done to evaluate the clinical efficacy and safety of desloratadine combined with dipyridamole, which is a platelet adhesion inhibitor in the treatment of CU. A randomized study was done in 64 autoimmunity CU patients with positive autologous plasma skin test (APST): 34 patients as treatment and 30 controls. The treatment group was treated with desloratadine and dipyridamole, and the control group was treated with desloratadine only. The efficiency and side‐effect were evaluated at the end of treatment. The levels of fragment F1+2 were measured by enzyme‐linked immunosorbent assay in all patients at pre‐ and post‐treatment. The clinical effectiveness rates of treatment and control group were, respectively, 85.20% (21 cured, 8 obvious effectiveness) and 70% (14 cured, 7 obvious effectiveness); they have a significant difference (x = 4.09, P < 0.05). Before treatment, the weals and pruritus in the treatment and control group were, respectively, (1.74 ± 0.90, 1.79 ± 0.73) and (1.67 ± 0.84, 1.73 ± 0.78). After treatment, the weals and pruritus in treatment and control group were, respectively, (0.38 ± 0.73, 0.58 ± 0.89) and (0.67 ± 0.96, 1.10 ± 1.12). These findings provide new insights into the pathogenesis of CU and suggest new therapeutic opportunities for treating this disease.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18081747</pmid><doi>10.1111/j.1468-3083.2007.02511.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2008-04, Vol.22 (4), p.487-492 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70430161 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Adolescent Adult Aged Child Child, Preschool Chronic Disease chronic urticaria (CU) desloratadine dipyridamole Dipyridamole - administration & dosage Dipyridamole - therapeutic use Drug Therapy, Combination F1+2 Female Histamine H1 Antagonists, Non-Sedating - administration & dosage Histamine H1 Antagonists, Non-Sedating - therapeutic use Humans Loratadine - administration & dosage Loratadine - analogs & derivatives Loratadine - therapeutic use Male Middle Aged Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - therapeutic use Skin Tests Treatment Outcome Urticaria - drug therapy |
| title | Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A39%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20desloratadine%20combined%20with%20dipyridamole%20in%20the%20treatment%20of%20chronic%20urticaria&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Khalaf,%20AT&rft.date=2008-04&rft.volume=22&rft.issue=4&rft.spage=487&rft.epage=492&rft.pages=487-492&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/j.1468-3083.2007.02511.x&rft_dat=%3Cproquest_cross%3E70430161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70430161&rft_id=info:pmid/18081747&rfr_iscdi=true |